HTB South

CROI 22 (Retrovirus) Seattle 2015

2015 Conference on Retroviruses and Opportunistic Infections (CROI), 23-26 February 2015, Seattle

Pipeline ART: tenofovir alafenamide (TAF)

Pipeline ART: maturation inhibitors and an attachment inhibitor

No HIV transmissions between gay couples when viral load is undetectable: preliminary results from “Opposites Attract” study in Australia, Thailand and Brazil

PrEP reduced HIV risk by at least 86% in PROUD: no transmissions likely from people taking meds

“On demand” PrEP dosing in IPERGAY: 86% reduced risk of HIV, no transmissions with active drug use

Other HIV PrEP studies at CROI 2015: implementation of oral PrEP and problems with tenofovir gel

Early HIV treatment and isoniazid prophylaxis: why TEMPRANO results do not yet support universal ART at CD4 counts >500

Featured Unintended pregnancies with levonorgestrel implant due to drug interactions with efavirenz-based ART

Featured Three drug ART best for preventing vertical transmission to infants: results from the PROMISE study

3 in 5 breastfeeding women with viral load >1,000 copies/mL are undiagnosed in Kenya, Malawi and South Africa

Point of care HIV PCR test for infant diagnosis: good performance but poorer results in youngest age group

Weekend-off ART is non-inferior to continuous ART in young people taking efavirenz-based regimens: results from BREATHER study

Increased cardiovascular risks in HIV positive children in Uganda and Zambia partially reversed by ART

Lopinavir/ritonavir in young children is superior to nevirapine after five years: results from long term follow up of IMPAACT P1060

Long-term safety and efficacy of tenofovir in children

UK case of HIV remission: ten years off-ART in patient with prior progression and treated during seroconversion